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Abstract
Aims: The aim of the study was to test if pharmacological intervention by valproic acid (VPA) treatment can modulate the
fibrinolytic system in man, by means of increased acute release capacity of tissue plasminogen activator (t-PA) as well as an
altered t-PA/Plasminogen activator inhibitor -1 (PAI-1) balance. Recent data from in vitro research demonstrate that the
fibrinolytic system is epigenetically regulated mainly by histone deacetylase (HDAC) inhibitors. HDAC inhibitors, including
VPA markedly upregulate t-PA gene expression in vitro.
Methods and Results: The trial had a cross-over design where healthy men (n = 10), were treated with VPA (Ergenyl Retard)
500 mg depot tablets twice daily for 2 weeks. Capacity for stimulated t-PA release was assessed in the perfused-forearm
model using intra-brachial Substance P infusion and venous occlusion plethysmography. Each subject was investigated
twice, untreated and after VPA treatment, with 5 weeks wash-out in-between. VPA treatment resulted in considerably
decreased levels of circulating PAI-1 antigen from 22.2 (4.6) to 10.8 (2.1) ng/ml (p,0.05). It slightly decreased the levels of
circulating venous t-PA antigen (p,0.05), and the t-PA:PAI-1 antigen ratio increased (p,0.01). Substance P infusion resulted
in an increase in forearm blood flow (FBF) on both occasions (p,0.0001 for both). The acute t-PA release in response to
Substance P was not affected by VPA (p = ns).
Conclusion: Valproic acid treatment lowers plasma PAI-1 antigen levels and changes the fibrinolytic balance measured as t-
PA/PAI-1 ratio in a profibrinolytic direction. This may in part explain the reduction in incidence of myocardial infarctions by
VPA treatment observed in recent pharmacoepidemiological studies.
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Introduction
Cardiovascular disease is a major cause of death and disability
globally. Current preventive antithrombotic treatment options
target the coagulation cascade or the platelets. However, the drugs
must be dosed at a suboptimal clot-preventing level that leaves the
patient with a substantial residual risk, because of the dose-
depending risk of severe bleeding complications. In vivo the
endogenous fibrinolytic system has an important role in preventing
excessive clot formation. The balance between the key activator of
fibrinolysis, tissue plasminogen activator (t-PA), and its main
inhibitor plasminogen activator inhibitor-1 (PAI-1) is crucial for
the potency of the endogenous fibrinolytic system. The vascular
endothelium plays a pivotal role in its ability to produce and
release t-PA [1,2], while the main source of plasma PAI-1 is the
platelets [3,4]. The platelets retain high levels of mainly active
PAI-1 [5].
Several studies have implied that patients with coronary artery
disease (CAD) have impaired fibrinolytic capacity [6,7]. Impaired
acute t-PA release or increased plasma levels of PAI-1 predict
future adverse cardiovascular events [8,9,10]. Hypertension is also
associated with impaired fibrinolytic capacity [11,12,13]. This
impairment is improved by chronic anti-hypertensive treatment
[14], but not by acute blood pressure lowering [15], altogether
suggesting a smaller releasable intracellular t-PA pool. Recently,
pharmacological inhibition of PAI-1 has shown to protect against
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hypertension and vascular senescence in mice [16]. However,
there is no clinically available PAI-1 antagonist on the market.
Pharmacological tools to directly target the endogenous
fibrinolytic system have been lacking. Research by us and others
has shown that the t-PA-gene is sensitive to epigenetic control, and
several histone deacetylase (HDAC) inhibitors markedly upregu-
late the t-PA-gene expression in vitro [17,18,19]. Amongst all the
identified and developed HDAC inhibitors, valproic acid (VPA) is
already clinically well-established as one of the most commonly
used antiepileptic drugs worldwide [20].
It is of great clinical importance to establish if HDAC inhibitors
could be used in man to modulate the endogenous fibrinolytic
system. This hypothesis is supported by pharmacoepidemiological
studies, where VPA in contrast to other antiepileptic drugs was
found to significantly diminish the risk of myocardial infarction in
patients with epilepsy compared with controls [21,22].
This phase IIA study was an open prospective trial with a cross-
over design, investigating if treatment with clinically used doses of
VPA affects the fibrinolytic system in healthy subjects. The
primary endpoint of the study was if VPA induces a profibrinolytic
state in man. The fibrinolytic balance was measured as t-PA:PAI-1
antigen ratio as well as the stimulated capacity for acute t-PA
antigen release. Secondary effect variables were platelet number
and function.
Methods
Subjects
Ten healthy, non-smoking white male subjects, aged 50-70
years were recruited by advertisement in a local newspaper.
Patients with overt cardiovascular disease, hypertension, blood
lipid derangement or diabetes mellitus were not included. The
study protocol was approved by the Ethics Committee of the
University of Gothenburg (Dnr: 297-09) and by the Medical
Products Agency in Sweden (EudraCT Number: 2009-011723-
31). The trial was conducted according to the Declaration of
Helsinki. The nature, purpose and potential risks of the study were
carefully explained to each subject before written informed
consent was obtained. The study was performed at The
Wallenberg Laboratory for Cardiovascular and Metabolic Re-
search, Sahlgrenska University Hospital, Gothenburg, Sweden.
The protocol for this trial and supporting TREND checklist are
available as supporting information; see Checklist S1 and Protocol
S1.
Study design
A baseline physical examination, ECG and analysis of routine
blood chemistry were initially performed. After inclusion, the
capacity for acute stimulated t-PA release was assessed with the
perfused-forearm model [23,24]. The study had a cross-over
design (Figure 1) where the subjects were allocated to group A
(n = 5) or B (n= 5). Group A received Ergenyl Retard (Sanofi,
500 mg b.i.d.) for two weeks before the first examination while
group B received Ergenyl Retard two weeks before the second
examination. There was a wash-out period of 5 weeks between the
two perfused forearm experiments. The responsible physician for
the study had continuous contact with the study subjects
throughout the whole study to minimize the risk for dropouts or
reduced compliance.
The perfused-forearm study
The subjects attended the laboratory after an overnight fast.
They had previously been instructed to refrain from coffee for
12 hours and from exhaustive physical exercise and alcohol for
24 hours. A 4 French arterial catheter (Careflow, Becton
Dickinson) was introduced percutaneously with modified Seldinger
technique into the brachial artery in the non-dominant arm. An
indwelling cannula was placed retrogradely into a deep ipsilateral
antecubital vein for blood sampling. Intra-arterial blood pressure
was recorded by an electrical transducer connected to a SC 9000
monitor (Siemens Medical Systems Inc). After each venous blood
sampling, forearm blood flow (FBF) was assessed by venous-
occlusion plethysmography with a mercury-in-silastic strain gauge
using the MAPPC software (Elektromedicin AB). Means of 3 to 5
recordings were expressed in millilitres per minute and litre of
tissue. Intra-observer and inter-observer coefficients of variation in
our laboratory have previously been reported to be, on the
average, 5.6% and 4.6%, respectively [14]. The laboratory
assistant, who analyzed the forearm blood flow curves, was
blinded for the treatment status of the subjects.
After cannulation of the artery, 30 minutes were allowed before
starting the experiment with a baseline recording for 15 minutes.
Thereafter, Substance P (Substance P, Bachem) at the concentra-
tion of 8 pmol/mL, was infused for 20 minutes into the brachial
artery at a constant rate of 1 mL/min. Post-infusion recordings
were performed for 10 minutes. The dose of Substance P was
chosen to obtain maximal t-PA release without systemic effects.
During pre- and post-infusion baseline periods, blood samples
were collected simultaneously from the brachial artery and vein.
During Substance P infusion, venous blood samples were obtained
at 1.5, 3, 6, 9, 12, 15, and 18 min. To avoid interruption of the
infusion, arterial blood was obtained only at baseline and at the
end of the infusion and in-between values were interpolated from
these values. Blood was collected in chilled, non-vacuated tubes
containing 1/10 vol. 0.45 M sodium citrate buffer pH 4.3 (in-
house made), for determination of fibrinolytic proteins. Tubes
were kept on ice until plasma was isolated by centrifugation at 4uC
and 2000 g for 20 min. Plasma aliquots were immediately frozen
and stored at 270uC until assay.
Biochemical analyses
Plasma concentrations of total t-PA antigen and PAI-1 antigen
were determined by ELISA (TintElize t-PA, Triolab; Coalize PAI-
1, Chromogenix AB) according to manufacturer protocol. Both
assays detect free and complexed forms of the respective proteins
with equal efficiency, according to the product sheets. The linear
correlation coefficient between free and complexed t-PA was 0.99.
Samples from one experiment were assayed in duplicate on the
same microtest plate. Blood chemistry analyses were performed by
standard methods at the Department of Clinical Chemistry at the
Sahlgrenska University Hospital. Platelet function was analysed
using multiple electrode aggregometry according to manufacturer
protocol (Multiplate; Verum Diagnostica GmbH, Munich,
Germany). The platelet function was analysed with ADP-
(adenosine-diphospate), ASPI- (arachidonic acid), TRAP- (throm-
binreceptor peptide) and RISTO-test (ristocetin).
Calculations
FBF was interconverted to forearm plasma flow (FPF) by
hematocrit. Venoarterial concentrations gradients were obtained
by subtraction of readings in simultaneously collected venous and
arterial samples. Net release or uptake rates for t-PA were
calculated as the venoarterial concentration gradient times FPF.
Statistical analysis
Unless otherwise stated, values are presented as mean and
standard error of the mean (SEM). Responses to VPA and
Substance P were analysed using paired t-test, 2-way ANOVA
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(treatment/no treatment and time), one-way ANOVA for
repeated measurements as well as the non-parametric Binomial
and Related-Samples Wilcoxon Signed Rank Test. Findings were
considered significant at p,0.05. All statistical analyses were
performed with SPSS (version 18.0, SPSS, Chicago, Illinois).
A pre-study sample size analysis was performed using an
estimated effect size of 40% along with a within-group variability
of 20% of the total response, power of 0.8 and an a value of 0.05,
which provided an estimated sample size of 10.
Results
11 potential subjects were enrolled in the study after responding
to the advertisement in the local newspaper. 10 subjects were
included in the trial. The complete data range from participant
recruitment to the last visit of the last subject participating in the
study was 4th September to 30th November 2011. Baseline
characteristics of the study subjects are shown in Table 1. All
ten study subjects completed the study. There were no adverse
events during the study. The compliance for drug administration
was 100%.
Hemodynamic responses
Baseline hemodynamic and fibrinolytic variables before the two
infusion studies are shown in Table 2. Baseline FBF was similar in
VPA treated and untreated patients (p = ns, t-test, Table 2).
Systolic and diastolic blood pressure levels were unaffected by
VPA (p= ns, t-test). Intra-brachial Substance P infusion resulted in
a significant increase in FBF on both occasions (p,0.0001 for
both, ANOVA). FBF responses to Substance P infusion showed a
tendency to suppression after VPA treatment, compared to
untreated subjects (p = 0.057, 2-way ANOVA, Figure 2).
t-PA baseline levels and responses
VPA decreased baseline venous t-PA antigen levels by
approximately 20% (p,0.05, t-test, Table 2). In 9 of 10 patients
baseline t-PA antigen decreased after VPA treatment (p = 0.02,
and p=0.01, Binomial Test and Related-Samples Wilcoxon
Signed Rank Test, respectively). Baseline t-PA release was 2.16
(3.3) and 3.27 (1.4) ng/min/L tissue during untreated and VPA
treated conditions, respectively (p = ns, t-test).
The t-PA antigen release in response to intra-brachial Substance
P infusion was not affected by VPA treatment (p = ns, 2-way
ANOVA, Figure 3). The average time to peak t-PA secretion in
untreated and treated subjects was 13.2 (1.7) and 11.0 (2.1)
minutes, respectively (p = ns, t-test).
Plasminogen activator inhibitor-1 levels
Circulating plasma levels of PAI-1 were significantly reduced
from 22.2 (4.6) to 10.8 (2.1) ng/ml after VPA treatment (p,0.05,
t-test, Figure 4). In all 10 patients baseline venous PAI-1 antigen
decreased after VPA treatment (p = 0.002, and p= 0.005 for
Binomial Test and Related-Samples Wilcoxon Signed Rank Test,
respectively). During substance P infusion, there was no detectable
release of PAI-1 from the forearm, either in the treated or
untreated condition (data not shown, p = ns).
Figure 1. Consort flow diagram.
doi:10.1371/journal.pone.0107582.g001
Profibrinolytic Effect of Valproic Acid in Man
PLOS ONE | www.plosone.org 3 October 2014 | Volume 9 | Issue 10 | e107582
Fibrinolytic balance
The ratio of baseline venous t-PA:PAI-1, and baseline arterial t-
PA:PAI-1 antigens were both significantly increased by VPA
treatment (p,0.01 for both, t-test, Table 2).
Platelet count and aggregation tests
VPA treatment did not alter the platelet counts (p = ns). Platelet
aggregation responses were evaluated in whole blood samples
using Multiplate analysis induced by ASPI, ADP, TRAP, and
RISTO-low and -high, respectively. Platelet aggregation was not
affected by VPA-treatment (data not shown, p= ns).
Discussion
In the present study we examined if treatment with valproic acid
affects the regulation of the main enzymes of the fibrinolytic
system in healthy man. Our main finding was markedly reduced
circulating plasma PAI-1 antigen levels after VPA treatment. The
capacity for acute stimulated t-PA antigen release was not affected.
By contrast, basal levels of t-PA and PAI-1 antigen were reduced
by 19% and 51%, respectively. This may indicate that the
fibrinolytic balance between t-PA and PAI-1 antigen levels was
altered, resulting in a profibrinolytic state in man.
Our finding of diminished circulating levels of PAI-1 antigen
after VPA treatment is very interesting and might translate into
decreased cardiovascular risk, as PAI-1 is the main inhibitor of
active t-PA, and thereby of vascular fibrinolysis [25]. Angiotensin-
converting enzyme inhibitors (ACE-I) have also been shown to
have a suppressive effect on PAI-1 levels, altering the fibrinolytic
balance in favor of fibrinolysis [13]. Results from large placebo-
controlled trials regarding patients with ventricular dysfunction
after myocardial infarction have shown a significant decrease in
the incidence of coronary events in patients treated with ACE-I,
irrespectively of its effect on the blood pressure [13]. The favorable
impact of ACE-I on the fibrinolytic balance might contribute to
the observed cardioprotective effect. However, no specific study
exists indicating that drugs that improve the fibrinolytic balance
are superior in terms of reduction in stroke or coronary events,
although indirect evidences support this possibility. Further studies
are necessary to elucidate the clinical impact of an improved
fibrinolytic balance as well as the mechanism behind the down-
regulatory effect of VPA on PAI-1 levels. Epigenetic regulatory
mechanisms on PAI-1 expression have not been studied so far in
humans. In vitro clinical doses of VPA did not have any effect on
PAI-1 gene transcription in human umbilical vein endothelial cells
[17]. However, in an in vivo model in mice we have observed a
suppression of PAI-1 mRNA in aortic endothelial cells after one
week pretreatment with VPA (unpublished data).
A well known side effect of VPA is thrombocytopenia but we did
not observe any suppression of platelet count or function after 2
weeks of VPA treatment (data not shown). Previous studies have
shown small effects on platelet count only in a minority of patients
Table 1. Baseline characteristics of the study subjects (n = 10).
Parameter Mean (SEM)
Age, years 64.1 (1.4)
Systolic blood pressure, mmHg 137.0 (4.9)
Diastolic blood pressure, mmHg 80.6 (1.8)
Body mass index, kg/m2 28.9 (0.9)
Total cholesterol, mmol/L 5.2 (0.3)
LDL cholesterol, mmol/L 3.7 (0.3)
HDL cholesterol, mmol/L 1.1 (0.1)
Triglycerides, mmol/L 1.3 (0.2)
Hemoglobin, g/L 147.4 (3.4)
Creatinine, mmol/L 88.8 (5.0)
Glucose, mmol/L 5.7 (0.2)
High sensitive CRP, mg/L 1.6 (0.3)
Abbreviations: CRP = C-reactive protein, LDL = low density lipoprotein, HDL = high density lipoprotein.
doi:10.1371/journal.pone.0107582.t001
Table 2. Study parameters.
Parameter Before VPA After VPA P-value
Serum valproate, mmol/L 0 426 (25) ,0.0001
Baseline FBF, ml/min/100 ml tissue 2.84 (0.19) 2.73 (0.18) ns
Baseline venous t-PA antigen, ng/ml 10.54 (0.65) 8.57 (0.41) ,0.05
Baseline t-PA release, ng/min/L tissue 2.16 (3.3) 3.27 (1.4) ns
Baseline venous PAI-I antigen, ng/ml 22.2 (4.6) 10.8 (2.1) ,0.05
Baseline venous t-PA:PAI-1 ratio 0.74 (0.17) 1.03 (0.17) ,0.01
Baseline arterial t-PA:PAI-1 ratio 0.85 (0.17) 1.19 (0.20) ,0.01
doi:10.1371/journal.pone.0107582.t002
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Figure 3. Net forearm release rates of t-PA antigen during baseline and in response to 20 min infusion of Substance P (8 pmol/min)
in untreated (&) and VPA treated (q) healthy subjects (n =10). Baseline measurements 15 min before and 10 min after the infusion. 2-way
ANOVA, mean and SEM.
doi:10.1371/journal.pone.0107582.g003
Figure 2. Forearm blood flow during baseline and in response to 20 min infusion of Substance P (8 pmol/min) in untreated (&) and
VPA treated (q) healthy subjects (n =10). Baseline measurements 15 min before and 10 min after the infusion. 2-way ANOVA, mean and SEM.
doi:10.1371/journal.pone.0107582.g002
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after long-term treatment [26]. Thus, the diminished PAI-1 after
VPA cannot be explained by reduced platelet number.
We have previously demonstrated a marked upregulation of the
t-PA-gene expression by VPA in vitro mainly through its HDAC
inhibitory effect [17,18]. The upregulation in cultured human
endothelial cells was reflected by both increased mRNA and
protein levels. This effect was established within 24 hours and was
observed in human endothelial cells from coronary arteries, aorta
and the umbilical vein. The upregulation of t-PA was 10–15 fold
compared to basal levels for both mRNA and protein at a
concentration of 3 mM of VPA in the cell culture medium.
However, the effect on t-PA-gene expression was highly concen-
tration-dependent, and within the therapeutic range used in the
clinical practice for prevention of epilepsy seizures we observed a
2–4 fold induction of t-PA in vitro [17]. However, to extrapolate
the optimal concentration from in vitro to in vivo is complex and
requires further studies. In this study the mean serum valproate
concentration in the treated subjects was 426 mmol/L, which is in
the lower part of the therapeutic concentration range (300–
700 mmol/L). Further studies will have to elucidate the optimal
dose as well as treatment duration effects on the fibrinolytic
balance.
Most of the t-PA in plasma is complex bound to PAI-1 during
baseline conditions [27]. It is only the free fraction of t-PA that is
enzymatically active. There is a strong association between PAI-1
and t-PA antigen levels [28]. A possible explanation for this is that
the hepatic clearance of t-PA/PAI-1 complex is slower than for
free t-PA. Thus, the hepatic clearance of total t-PA is inversely
related to PAI-1 antigen levels, and basal t-PA antigen level is in
part a surrogate measure of PAI-1 level [28]. This could explain
our finding of decreased t-PA antigen at baseline, as a result from
diminished PAI-1 antigen resulting in a reduced fraction of t-PA/
PAI-1 complexes.
Both t-PA and PAI-1 levels are risk factors for a first myocardial
infarction [9,29,30], and they are also significant risk markers for
recurrent myocardial infarction [31,32]. It is not obvious,
however, why elevated t-PA antigen levels are associated with
coronary events, since t-PA is the key profibrinolytic enzyme. We
have previously demonstrated that baseline venous plasma t-PA
(or PAI-1) does not predict local fibrinolytic capacity [33], and it is
likely that it is the local t-PA release capacity that is essential for
the protection against occlusive thrombus formation. There are
alternative explanations why systemic t-PA is a cardiovascular risk
factor. First, baseline t-PA antigen might be reflective of the
amount of PAI-1 [30]. The t-PA levels may also reflect the acute
phase response in CAD or may indicate endothelial dysfunction or
net activation of the fibrinolytic system due to underlying
atherosclerosis [9].
Results from two recent pharmacoepidemiological studies
suggest that VPA may have beneficial cardiovascular effects, as
it was found to diminish the risk of myocardial infarction and
stroke in large cohorts [21,22]. A possible explanation to the
observed cardiovascular protection by VPA might be related to the
diminished levels of PAI-1 and the beneficial fibrinolytic balance,
measured as t-PA:PAI-1 ratio in the present study.
There are several limitations of the study. First, we have only
stimulated the endothelium with Substance P, and it still remains
unknown if another physiological endothelium agonist could have
led to increased stimulated t-PA release capacity. Second, the
healthy subjects in this study might have a normal t-PA production
and release capacity from the beginning, and VPA cannot be
expected to increase the intracellular t-PA pool to supra-
physiological levels. Third, as VPA may decrease the expression
of endothelial nitric oxide synthase [34], we observed a tendency
to impaired endothelium-dependent vasodilation after VPA. This
could have influenced the measurements of stimulated t-PA release
capacity. Fourth, fibrinolytic function was measured in this study
as dependent on t-PA and PAI-1 antigen levels in plasma. It would
be of value to have a more functional assay. However, since the
endogenous fibrinolytic system is dependent on the acute release of
t-PA upon stimulation from the local endothelial cell layer,
functional assays such as clot lysis, thrombo-elastogram are
probably not relevant for testing the hypothesis. Finally, the
perfused forearm model might not be the optimal means to assess
Figure 4. Baseline venous and arterial plasminogen activator inhibitor-1 (PAI-1) antigen levels in untreated (&) and VPA treated
(grey square) subjects. *p,0.05, paired t-test, untreated versus treated.
doi:10.1371/journal.pone.0107582.g004
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the local fibrinolytic capacity in healthy subjects, where effects on
the fibrinolytic system could be more difficult to prove locally in
the forearm model compared to the systemic level. Further studies
are needed to elucidate the mechanism behind the improved
fibrinolytic balance as well as studies in patients with defect
endogenous fibrinolytic system. There is a possibility that patients
with a defect fibrinolytic system may respond differently to VPA
treatment than healthy controls. It may be easier to normalize an
impaired t-PA production compared with inducing supra-physi-
ological levels of intracellular t-PA.
Conclusion
Treatment with the epigenetic modifier valproic acid did not
affect the local stimulated t-PA release capacity from forearm in
healthy men. On the systemic level, however, valproic acid
significantly decreased plasma levels of PAI-1 antigen, and altered
the balance between t-PA and PAI-1 antigen. This may cause a
profibrinolytic state in man. The divergent results might depend
on the cohort of apparently healthy men, where effects might be
more difficult to show locally than systemically. Further studies are
motivated to evaluate the effects of valproic acid or other histone
deacetylase inhibitors on the fibrinolytic system in patients with
impaired capacity for endogenous fibrinolysis, e.g. in patients with
manifest atherosclerosis.
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